Novartis AG - Clinical Immunology

ZURICH (Reuters) - A third late-stage trial of Novartis' multiple sclerosis drug Gilenya did not throw up any new safety issues with the pill, going some way to alleviating concerns about possible risks linked to the potential blockbuster.The study results come just ...

Efforts underway to educate community and healthcare providers on Gilenya to enable informed treatment decisions. - Novartis launching initiatives to support broad patient access, including prescription benefits investigation services, co-pay programs, and inclusion of Gilenya in Novartis Patient Assistance Program. Novartis Pharmaceuticals ...

LONDON (Reuters) - An experimental new antibody drug from Novartis has proved safe and effective in treating three diseases involving inflammation -- scaly skin, arthritis and a sore eye condition, data showed on Wednesday.Novartis researchers said the early-stage trials suggested the drug, ...

The FDA approval of the first oral drug for relapsing remitting multiple sclerosis (RRMS) in the US went pretty much as expected, especially in light of the unanimous June 10th recommendation from an independent committee to the US Food and Drug Administration ...

The coolest thing about Novartis' new MS drug Gilenya is that it is derived from an immune suppressant first found in a fungus that kills cicadas in China and Japan. "It will certainly be a blockbuster if things play out as we ...

Today, Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis - the most common forms of the disease. Gilenya reduces ...

We have a winner in the U.S. race to market a pill for multiple sclerosis - Novartis! Biogen shares slid today on fears Gilenya will compete with its existing MS therapies Avonex and Tysabri. Forbes' The Medicine Show blog notes the surprise ...

ZURICH (Reuters) - Swiss drugmaker Novartis AG's multiple sclerosis pill Gilenya won U.S. backing, putting it ahead of German rival Merck KGaA in the race to be first with an oral treatment in the United States.The U.S. Food and Drug Administration's backing ...

The FDA today approved Novartis' Gilenya, the first oral drug for multiple sclerosis (MS). Gilenya treats the relapsing form of MS. The drug significantly reduces MS attacks. In MS, white blood cells attack the myelin sheaths that protect nerve cells. Two fatal ...

Novartis gains Food and Drug Administration approval for new multiple sclerosis drugFederal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.The Food and ...

Previous

1
2

Topic: Novartis AG

Gilenya trial could ease safety worries

Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya

Experimental Novartis drug helps range of diseases

Gilenya (aka Fingolimod): When and How Much?

From Cicada Fungus To MS Drug: How Big Will Novartis' New Pill Be?

Novartis Gains FDA Approval For Gilenya, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly Reduce Relapses And Delay Disability Progression

Novartis Drug First to Cross Oral MS Therapy Finish Line in U.S.

Novartis gets first U.S. backing for MS pill

Gilenya, First Oral MS Drug, Gets FDA Nod

Novartis gains FDA approval for new MS drug

Photo Gallery

From Around the Web

Video Gallery

Follow this Topic with...